Journals / Neurological sciences and neurophysiology (Online) / 2019 / Cilt: 36 - Sayı: 3

Inflammatory biomarkers in epilepsy

Pages
129–135
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Herein, we detail the clinical and immunological significance of several factors of inflammation that may in due time serve as biomarkers of epilepsy in an effort to potentially inspire the researchers towards the development of reliable prognostic biomarkers for epilepsy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Epilepsy affects millions of people worldwide and has a great burden on world health.
📊
Key Findings & Data:Improvement of seizure outcomes mostly relies on establishment of individualized risk factors for epileptogenesis and drug resistance.
💡
Conclusion & Impact:Herein, we detail the clinical and immunological significance of several factors of inflammation that may in due time serve as biomarkers of epilepsy in an effort to potentially inspire the researchers towards the development of reliable prognostic biomarkers for epilepsy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Epilepsy affects millions of people worldwide and has a great burden on world health. Improvement of seizure outcomes mostly relies on establishment of individualized risk factors for epileptogenesis and drug resistance. Several circulating molecules could serve as diagnostic and prognostic biomarkers at different stages of the disease. Inflammatory markers, blood-brain barrier markers, oxidative stress markers, microRNAs, autoantibodies, hormones and growth factors are promising fields of research for biomarkers in epilepsy. Several experimental studies and only a few clinical studies have revealed associations between inflam-matory biomarkers and clinical outcomes of epilepsy. Herein, we detail the clinical and immunological significance of several factors of inflammation that may in due time serve as biomarkers of epilepsy in an effort to potentially inspire the researchers towards the development of reliable prognostic biomarkers for epilepsy.

🔖

Cite This Article

KARAASLAN, Z., TÜZÜN, E. (2019). Inflammatory biomarkers in epilepsy. Neurological sciences and neurophysiology (Online), Cilt: 36 - Sayı: 3, 129–135. https://ajindex.com/articles/290588

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. van Dijkman SC, Wicha SG, Danhof M, Della Pasqua OE. Individualized dosing algorithms and therapeutic monitoring for antiepileptic drugs. Clin Pharmacol Ther 2018; 103: 663-673. [CrossRef] 2. Engel J Jr, Pitkänen A, Loeb JA, et al. Epilepsy biomarkers. Epilepsia 2013; 54: 61-69. [CrossRef] 3. Xanthos DN, Sandkühler J. Neurogenic neuroinflammation: inflammatory CNS reactions in response to neuronal activity. Nat Rev Neurosci 2014; 15: 43-53. [CrossRef] 4. Vezzani A, French J, Bartfai T, Baram TZ. The role of inflammation in epilepsy. Nat Rev Neurol 2011; 7: 31-40. [CrossRef] 5. Walker LE, Janigro D, Heinemann U, Riikonen R, Bernard C, Patel M. WONOEP appraisal: Molecular and cellular biomarkers for epilepsy. Epilepsia 2016; 57: 1354-1362. [CrossRef] 6. Vezzani A, Friedman A. Brain inflammation as a biomarker in epilepsy. Biomark Med 2011; 5: 607-614. [CrossRef] 7. Ravizza T, Gagliardi B, Noé F, Boer K, Aronica E, Vezzani A. Innate and adaptive immunity during epileptogenesis and spontaneous seizures: evidence from experimental models and human temporal lobe epilepsy. Neurobiol Dis 2008; 29: 142-160. [CrossRef] 8. Hulkkonen J, Koskikallio E, Rainesalo S, Keränen T, Hurme M, Peltola J. The balance of inhibitory and excitatory cytokines is differently regulated in vivo and in vitro among therapy resistant epilepsy patients. Epilepsy Res 2004; 59: 199-205. [CrossRef] 9. Diamond ML, Ritter AC, Failla MD, et al. IL-1β associations with posttraumatic epilepsy development: a genetics and biomarker cohort study. Epilepsia 2014; 55: 1109-1119. [CrossRef] 10. Balosso S, Ravizza T, Aronica E, Vezzani A. The dual role of TNF-α and its receptors in seizures. Exp Neurol 2013; 247: 267-271. [CrossRef] 11. Vezzani A, Maroso M, Balosso S, Sanchez MA, Bartfai T. IL-1 receptor/Toll-like receptor signaling in infection, inflammation, stress and neurodegeneration couples hyperexcitability and seizures. Brain Behav Immun 2011; 25: 1281-1289. [CrossRef] 12. Pollard JR, Eidelman O, Mueller GP, et al. The TARC/sICAM5 ratio in patient plasma is a candidate biomarker for drug resistant epilepsy. Front Neurol 2012; 3: 181. [CrossRef] 13. Basaran N, Hincal F, Kansu E, Ciger A. Humoral and cellular immune parameters in untreated and phenytoin-or carbamazepine-treated epileptic patients. Int J Immunopharmacol 1994; 16:1071-1077. [CrossRef] 14. Cerri C, Genovesi S, Allegra M, et al. The Chemokine CCL2 mediates the seizure-enhancing effects of systemic inflammation. J Neurosci 2016; 36: